Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C22H27FN3O6S · 0.5 Ca
CAS Number:
Molecular Weight:
500.57
UNSPSC Code:
12352200
NACRES:
NA.77
Product Name
Rosuvastatin calcium, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D +12 to +18°, c = 1 in methanol: water (1:1)
storage condition
desiccated
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
SMILES string
[Ca+2].Fc3ccc(cc3)c4nc(nc(c4\C=C\[C@@H](O)C[C@@H](O)CC(=O)[O-])C(C)C)N([S](=O)(=O)C)C.Fc1ccc(cc1)c2nc(nc(c2\C=C\[C@@H](O)C[C@@H](O)CC(=O)[O-])C(C)C)N([S](=O)(=O)C)C
InChI
1S/2C22H28FN3O6S.Ca/c2*1-13(2)20-18(10-9-16(27)11-17(28)12-19(29)30)21(14-5-7-15(23)8-6-14)25-22(24-20)26(3)33(4,31)32;/h2*5-10,13,16-17,27-28H,11-12H2,1-4H3,(H,29,30);/q;;+2/p-2/b2*10-9+;/t2*16-,17-;/m11./s1
InChI key
LALFOYNTGMUKGG-BGRFNVSISA-L
General description
Rosuvastatin calcium (ROS) has a molecular mass of 1001.14. ROS is a member of the "statins" group and is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.
Application
Rosuvastatin calcium has been used to determine the effect of the treatment with SIM, rosuvastatin or PRA on cholesterol and HMGCR levels in HeLa cells and to evaluate the in vivo effects of statins on glucose homeostasis.
Biochem/physiol Actions
Rosuvastatin calcium is a HMG-CoA reductase inhibitor.
Rosuvastatin calcium is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin calcium is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy.
Hammer, et al.
Diabetologia (2023)
Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.
Wang HJ, et al.
Autophagy, 11(11), 2089-2101 (2015)
Analytical Methods for the Determination of Rosuvastatin in Pharmaceutical Formulations and Biological Fluids: A Critical Review.
Angelo ML, et al.
Critical Reviews in Analytical Chemistry, 48(4), 317-329 (2018)